E6AP Promotes a Metastatic Phenotype in Prostate Cancer

Cristina Gamell; Ivona Bandilovska; Twishi Gulati; Arielle Kogan; Syer Choon Lim; Zaklina Kovacevic; Elena A. Takano; Clelia Timpone; Arjelle D. Agupitan; Cassandra Litchfield; Giovanni Blandino; Lisa G. Horvath; Stephen B. Fox; Scott G. Williams; Andrea Russo; Enzo Gallo; Piotr J. Paul; Catherine Mitchell; Shahneen Sandhu; Simon P. Keam; Sue Haupt; Des R. Richardson; Ygal Haupt

iScience (Dec 2019)

E6AP Promotes a Metastatic Phenotype in Prostate Cancer

Cristina Gamell,
Ivona Bandilovska,
Twishi Gulati,
Arielle Kogan,
Syer Choon Lim,
Zaklina Kovacevic,
Elena A. Takano,
Clelia Timpone,
Arjelle D. Agupitan,
Cassandra Litchfield,
Giovanni Blandino,
Lisa G. Horvath,
Stephen B. Fox,
Scott G. Williams,
Andrea Russo,
Enzo Gallo,
Piotr J. Paul,
Catherine Mitchell,
Shahneen Sandhu,
Simon P. Keam,
Sue Haupt,
Des R. Richardson,
Ygal Haupt

Affiliations

Cristina Gamell: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia
Ivona Bandilovska: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia
Twishi Gulati: Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
Arielle Kogan: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia
Syer Choon Lim: Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia
Zaklina Kovacevic: Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia
Elena A. Takano: Department of Pathology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia
Clelia Timpone: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia
Arjelle D. Agupitan: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia
Cassandra Litchfield: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia
Giovanni Blandino: IRCCS Regina Elena National Cancer Institute, Rome, Italy
Lisa G. Horvath: The Chris O'Brien Lifehouse, Sydney, NSW 2050, Australia; Garvan Institute of Medical Research, Sydney, NSW 2010, Australia
Stephen B. Fox: Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia
Scott G. Williams: Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
Andrea Russo: IRCCS Regina Elena National Cancer Institute, Rome, Italy
Enzo Gallo: IRCCS Regina Elena National Cancer Institute, Rome, Italy
Piotr J. Paul: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia
Catherine Mitchell: Department of Pathology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia
Shahneen Sandhu: Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
Simon P. Keam: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
Sue Haupt: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
Des R. Richardson: Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia; Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
Ygal Haupt: Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia; Department of Clinical Pathology, University of Melbourne, Parkville, VIC 3010, Australia; Department of Biochemistry and Molecular Biology, Monash University, Melbourne 3800, Australia; Corresponding author

Journal volume & issue: Vol. 22
pp. 1 – 15

Abstract

Read online

Summary: Although primary prostate cancer is largely curable, progression to metastatic disease is associated with very poor prognosis. E6AP is an E3 ubiquitin ligase and a transcriptional co-factor involved in normal prostate development. E6AP drives prostate cancer when overexpressed. Our study exposed a role for E6AP in the promotion of metastatic phenotype in prostate cells. We revealed that elevated levels of E6AP in primary prostate cancer correlate with regional metastasis and demonstrated that E6AP promotes acquisition of mesenchymal features, migration potential, and ability for anchorage-independent growth. We identified the metastasis suppressor NDRG1 as a target of E6AP and showed it is key in E6AP induction of mesenchymal phenotype. We showed that treatment of prostate cancer cells with pharmacological agents upregulated NDRG1 expression suppressed E6AP-induced cell migration. We propose that the E6AP-NDRG1 axis is an attractive therapeutic target for the treatment of E6AP-driven metastatic prostate cancer. : Biological Sciences; Cell Biology; Cancer Subject Areas: Biological Sciences, Cell Biology, Cancer

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal